Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (March 2018)
23 slides from Oncosil Medical's investor presentation, Mar 8, 2018
Slide 1: ASX Media Release: OncoSil Company Update Presentation
ASX/ Media Release 8 March 2018 OncoSil Company Update Presentation For personal use only Sydney, Australia, 8 March 2018: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pl
Slide 2: Forward Looking Statements
Forward Looking Statements This document contains certain forward-looking statements, relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “tar
Slide 3: Company Update: Advancing Pancreatic Cancer Treatment
For personal use only Company Update ASX.OSL March 2018 Advancing Pancreatic Cancer Treatment OncoSil Medical 1
Slide 4: OncoSil Medical Investment Highlights
OncoSil Medical | Investment Highlights For personal use only 1 Clear Commercialising a breakthrough implantation radiation mission treatment for Pancreatic cancer 2 Current and previous clinical studies demonstrate: Excellent Local Disease Control Sound Significant reduction in tumour size and
Slide 5: OncoSil first in class medical device for pancreatic cancer
OncoSil Medical OncoSilTM is a first in class medical device for the treatment of unresectable locally For personal use only advanced pancreatic cancer First in class technology Share price performance (1 year) Proprietary brachytherapy (internal radiation) medical Share price (acps) Volume (m) de
Slide 6: About the OncoSil device
About the OncoSilTM device An implantable radiotherapy medical device targeting pancreatic cancer For personal use only OncoSilTM is a single-use brachytherapy device Delivered through microparticles: 30-micron silicon particles contain beta-emitting Phosphorus-32 (32P) OncoSilTM Microparticles are
Slide 7: Implantation procedure
Implantation procedure Studies continue to show the device implantation is technically straightforward For personal use only Endoscope guided into the OncoSil™ injected OncoSilTM dose is upper intestine directly into the suspended in a tumour Using CT or real-time imaging, specially formulated the n
Slide 8: OncoSil at a potential value inflection point
OncoSil at a potential value inflection point The Company is well positioned to realise value of OncoSil™ device For personal use only Current focus Before 2015: 2016 to 2018: 2018 onwards: Demonstrate Satisfy regulatory Path to potential obligations commercialisation 4 studies show Secured US F
Slide 9: Clinical pathway overview
Clinical pathway overview PanCO and OncoPaC-1 to inform future studies For personal use only Future focus Phases: Current focus Studies to drive clinical adoption (EU & global) 2 concurrent trials, targeting 65 patients total and secure US FDA approval Trials: PanCO – 45 patients Company exploring c
Slide 10: PanCO study – positive results to date
PanCO study – positive results to date Positive clinical data on 20 patients (at Week 8) and 14 patients (at Week 16) For personal use only Patients recruited 38 patients enrolled in the study1 and implanted 28 patients implanted1 Excellent local Disease Control Rate (DCR) of 100% (Week 8) and
Slide 11: Significant opportunity for OncoSil
Significant opportunity for OncoSil For personal use only Current available treatment for pancreatic cancer The opportunity for OncoSil Surgery (resection), if diagnosed early enough Only two drugs to have made Chemotherapy (Gemcitabine and Abraxane) significant improvements in pancreatic canc
Slide 12: Positive reception at key conferences
Positive reception at key conferences Early study data presented at European Association of Nuclear Medicine (EANM) For personal use only Annual Congress and European Society of Medical Oncology (ESMO) The EANM is the largest organisation dedicated to Nuclear Medicine in Europe ESMO is Europe’s
Slide 13: Partnering with leading cancer centres
Partnering with leading cancer centres 15 leading cancer centres participating in Global Pancreatic Cancer clinical programme For personal use only Region Centre MD Anderson, Texas Johns Hopkins, Maryland Moffit Cancer Centre Florida Cedars Sinai Hospital, LA Guy’s & St Thomas’, London University of
Slide 14: Clear pathway to commercialisation
Clear pathway to commercialisation Strategic partners provide multiple paths to market to optimise value For personal use only Well positioned for commercialisation Potential paths to market Broad technology platform Treatment for multiple solid tumours Strategic licensing partners in all key geogra
Slide 15: Global opportunity and target markets
UK(Launch market) 1,2 Pancreatic cancer 8,747 Liver cancer 4,186 European Union1,2 For personal use only Pancreatic cancer 79,331 Liver cancer 51,785 Target markets Annual incidence China1,2 Global opportunity United States 1,2 Pancreatic cancer 65,727 Liver cancer 351,000 Pancreatic cancer US>$2.0b
Slide 16: Global commercial opportunity in excess of $2bn
Global Commercial opportunity in excess of $2bn 130,000 cases per year in US+EU alone: more than 70,000 of these could benefit from OncoSil For personal use only More than 70,000 relevant Locally OncoSil™ provides a suitable treatment to patients in EU and US alone advanced control the growth of the
Slide 17: OncoSil's commercial path has precedent
OncoSil’s commercial path has precedent Sirtex provides a useful case study to demonstrate the potential commercial journey For personal use only for OncoSil due to similarities in addressable market 24-Aug-00 5-Mar-02 Listed on the ASX with Phase II FDA approval for SIR-spheres achieved and Phase I
Slide 18: Sector M&A trends
Sector M&A trends Over A$2bn of acquisitions in February 2018 highlights attraction of early-stage For personal use only Australian biotech to global pharmaceutical players Acquiree Acquirer Consideration A$1.6 billion1 A$502 million1 A$120 million1 Date 30 Jan 2018 22 Feb 2018 6 Feb 2018 Premium 60
Slide 19: Board of Directors
Board of Directors For personal use only • Board and management are experienced leaders in the pharmaceutical and medical device space, having held senior positions at Cochlear (ASX:COH), Sirtex Medical (ASX:SRX), ABIVAX, Baxter International, Roche and more • Extensive leadership experience guiding
Slide 20: Highly experienced management team
Highly experienced management team Revamped leadership team For personal use only • Management team experienced leaders in the medical device space having held senior positions at Sirtex Medical (ASX:SRX) • Extensive leadership experience in clinical studies, commercialisation and manufacturing & op
Slide 21: Key catalysts in CY 2018
Key catalysts in CY 2018 Revamped leadership team For personal use only Target submission of 16 week 20 patient supplemental data to BSI by 31-May-18 CE Mark Target CE Mark certification Target EU first sales Continued recruitment into the Global Pancreatic Cancer clinical study Global Pancr
Slide 22: Important notice
Important notice For personal use only This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide an overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presenta
Slide 23: Daniel Kenny, CEO & Managing Director
For personal use only Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au OncoSil Medical Ltd www.oncosil.com.au T: +61 2 9223 3344 F: +61 2 9252 3988 OncoSil Medical 21